Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	2,937	2,809	2,093	1,517	1,123	789.39
Other Revenue	7.75	7.75	7.74	10	9.51	4.54
Revenue	2,945	2,817	2,100	1,527	1,132	793.93
Revenue Growth (YoY)	32.29%	34.13%	37.55%	34.86%	42.61%	8.81%
Cost of Revenue	192.67	184.47	140.2	171.01	126.99	85.65
Gross Profit	2,753	2,633	1,960	1,356	1,005	708.29
Selling, General & Admin	1,443	1,393	1,060	841.02	700.65	503.55
Research & Development	315.2	292.02	228.52	148.58	79.74	74.23
Other Operating Expenses	12.12	13.3	10.95	7.64	5.55	3.83
Operating Expenses	1,774	1,702	1,300	995.83	783.6	581.42
Operating Income	978.06	930.33	659.88	360.06	221.64	126.86
Interest Expense	-0.45	-0.45	-0.51	-0.62	-1.07	-2.46
Interest & Investment Income	6.95	6.99	10.17	8.09	7.84	3.67
Currency Exchange Gain (Loss)	-0.12	-0.12	-1.03	0.48	-0.47	-0.95
Other Non Operating Income (Expenses)	4.07	-0.09	-0.39	-0.25	-0.24	0.39
EBT Excluding Unusual Items	988.51	936.67	668.13	367.77	227.69	127.51
Gain (Loss) on Sale of Investments	0.92	0.88	2.65	0.4	1.8	3.96
Gain (Loss) on Sale of Assets	-0.06	-0.03	-0.87	0.03	-1.8	-1.13
Asset Writedown	-	-	-12.76	-	-	-
Other Unusual Items	-6.5	-6.5	-16.49	-12.27	-12.4	8.73
Pretax Income	982.87	931.03	640.65	355.93	215.29	139.07
Income Tax Expense	101.95	103.42	85.21	68.91	34.09	22.5
Net Income	880.92	827.6	555.45	287.02	181.2	116.57
Net Income to Common	880.92	827.6	555.45	287.02	181.2	116.57
Net Income Growth	46.80%	49.00%	93.52%	58.40%	55.44%	81.31%
Shares Outstanding (Basic)	408	408	405	404	403	402
Shares Outstanding (Diluted)	408	408	405	404	403	402
Shares Change (YoY)	0.58%	0.56%	0.29%	0.39%	0.18%	12.54%
EPS (Basic)	2.16	2.03	1.37	0.71	0.45	0.29
EPS (Diluted)	2.16	2.03	1.37	0.71	0.45	0.29
EPS Growth	45.95%	48.18%	92.96%	57.78%	55.17%	61.11%
Free Cash Flow	326.06	179.28	223.64	143.99	43.85	-26.2
Free Cash Flow Per Share	0.80	0.44	0.55	0.36	0.11	-0.07
Dividend Per Share	0.620	0.620	0.410	0.213	0.100	0.050
Dividend Growth	51.22%	51.22%	92.49%	113.00%	100.00%	100.00%
Gross Margin	93.46%	93.45%	93.33%	88.80%	88.78%	89.21%
Operating Margin	33.21%	33.02%	31.42%	23.58%	19.57%	15.98%
Profit Margin	29.91%	29.38%	26.45%	18.80%	16.00%	14.68%
Free Cash Flow Margin	11.07%	6.36%	10.65%	9.43%	3.87%	-3.30%
EBITDA	1,039	989.71	713.25	403.23	260.33	165.03
EBITDA Margin	35.28%	35.13%	33.96%	26.41%	22.99%	20.79%
D&A For EBITDA	60.89	59.38	53.37	43.17	38.69	38.17
EBIT	978.06	930.33	659.88	360.06	221.64	126.86
EBIT Margin	33.21%	33.02%	31.42%	23.58%	19.57%	15.98%
Effective Tax Rate	10.37%	11.11%	13.30%	19.36%	15.83%	16.18%
Revenue as Reported	2,817	2,817	2,100	1,527	1,132	793.93
Advertising Expenses	-	-	-	2.94	5.48	6.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.